Expert Highlights Applications of Proton Therapy in Radiation Oncology

Commentary
Video

The use of proton therapy may offer a more specific depth charge compared with conventional radiation, according to Timothy Chen, MD.

Administering proton therapy to pediatric populations with cancer may serve as a “great application” that helps patients avoid developing mutations and second cancers, says Timothy Chen, MD.

Chen, a board-certified radiation oncologist and medical director of the Central Nervous System Program at Jersey Shore University Medical Center and the director of Proton Therapy in the Department of Radiation Oncology at Hackensack Meridian Health, spoke with CancerNetwork® about the potential applications of proton therapy and benefits this modality may offer compared with standard radiation.

In addition to the potential utility of proton therapy among pediatric populations, Chen highlighted how this technique may demonstrate more precision than others based on what he described as a “depth charge.” For example, it may be possible to administer proton therapy to breast tumors while sparing the lungs from receiving any excess radiation.

Transcript:

Proton therapy is type of radiation but with a different particle hitting the target. If you think about conventional radiation like a pistol, proton [therapy] is like a cannon. It also has a great purpose with what’s called a depth charge. We can set a cannon to be explored at a certain depth. The conventional radiation comes and goes while passing through the structure. With proton therapy, we can say where I want to go and stop right there. With that, there are great applications.

No. 1 is in pediatric [patients with] cancer. Because a child is still growing, the conventional radiation can create mutations, and they could eventually develop a second cancer in their later life. Proton therapy is a particularly great design for pediatric patients [with] cancer; their chance of getting a mutation or a second cancer is smaller.

The second thing is about the depth charge. Because we can set the characteristic of this beam, we can treat quite a large area that’s not accessible with conventional radiation. For example, in breast cancer, the breast sits on top of the chest wall, and as we breathe, the lungs get in [the way and receive] the radiation. But because we can set the depth [with proton therapy], you can confine radiation to the breasts and not touch the lungs.

Recent Videos
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
Updated findings from the phase 3 EV-302 trial show enduring responses and survival improvements with enfortumab vedotin plus pembrolizumab.
AI-powered tools may help alleviate doctor burnout and give clinicians more time to directly engage with patients.
Artificial intelligence may have the potential to enrich pathology practices to help identify aspects of tumor biology not seen with the human eye.
Efficacy results from the MASAI trial preceded the creation of the UK-funded EDITH trial, assessing 5 AI platforms in 700,000 women undergoing mammography.
Related Content